Coeptis Therapeutics Holdings, Inc.
COEP
$15.92
-$0.04-0.25%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.67% | 36.40% | 40.11% | 54.33% | 43.68% |
| Total Depreciation and Amortization | 13.88% | 10.96% | 3.82% | 0.28% | 0.17% |
| Total Amortization of Deferred Charges | 307.93% | 269.27% | 10.73% | -- | -- |
| Total Other Non-Cash Items | 44.26% | -75.75% | -70.22% | -82.84% | -80.10% |
| Change in Net Operating Assets | -296.37% | -197.63% | -127.88% | -107.26% | 1,212.31% |
| Cash from Operations | -20.92% | -16.06% | 4.62% | 8.16% | -8.03% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 200.00% | -60.00% | 200.00% | -- | -- |
| Cash from Investing | 200.00% | -60.00% | 200.00% | -- | -- |
| Total Debt Issued | -50.50% | 211.12% | -25.50% | 184.62% | 300.00% |
| Total Debt Repaid | 69.89% | 84.42% | 61.50% | 46.86% | 68.67% |
| Issuance of Common Stock | 129.36% | -98.27% | -98.27% | -88.66% | -36.42% |
| Repurchase of Common Stock | -- | 88.89% | -- | -- | -71,328.57% |
| Issuance of Preferred Stock | 91.09% | 353.20% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -99.90% | -99.93% | 150.20% | 150.00% | 213.90% |
| Cash from Financing | 78.58% | 67.58% | 58.22% | 16.18% | 1,452.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,475.81% | 126.14% | 400.58% | 59.68% | 95.40% |